Forma Therapeutics, Inc.

Epizyme, Inc.

Blythe Thomson

Susan Ashwell

Wei Lu

Alan Collis

Duncan Walker

Patrick F Kelly

Jeff Davis

Roy MacFarlane Pollock

Eric Hedrick

Scott Richard Daigle

Nigel J Waters

Lu Wei

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Inhibiting mutant IDH-1

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation

Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation

The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Methods for treating cancer

Growing community of inventors

Cincinnati, OH, United States of America

Blythe Thomson